news

CUPERTINO, Calif., Feb. 28 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that it will present a corporate overview at three upcoming life sciences conferences in New York, NY. “SIGnificant Investment Options In Healthcare” conference, sponsored by Susquehanna International Group on Thursday, March 1st at 10:30 a.m. Eastern Time (7:30 a.m. Pacific Standard Time). “Positioning […]

CUPERTINO, Calif., Feb. 12 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the BIO CEO Investor Conference. The conference is being held at The Waldorf Hotel in New York, NY. James E. Brown, DVM, President and CEO, will be presenting at the conference on February 14, 2007 at 2:15 p.m.

CUPERTINO, Calif., Feb. 8 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months and year ended December 31, 2006. Total revenues were $5.4 million for the three months ended December 31, 2006, compared to $5.8 million for the same period in 2005. Net loss for the three months ended December

CUPERTINO, Calif., Feb. 5 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that we have entered into a long term manufacturing and supply agreement with Corium International, Inc. for TRANSDUR(TM)-Bupivacaine, a transdermal pain patch under development for patients suffering from Post-Herpetic Neuralgia (post-shingles pain or PHN). TRANSDUR-Bupivacaine is currently in Phase II clinical trials. Under

CUPERTINO, Calif., Jan. 30 /PRNewswire-FirstCall/ — In conjunction with DURECT Corporation’s (Nasdaq: DRRX) fourth quarter and year-end 2006 financial results press release, you are invited to listen to its conference call that will be broadcast live over the Internet on Thursday, February 8th, 2007 at 4:30 p.m. EST. (Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO ) What: DURECT Corporation’s

CUPERTINO, Calif., Jan. 29 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that we have entered into a long term manufacturing and supply agreement with Hospira Worldwide, Inc. (“Hospira”) (NYSE: HSP) for POSIDUR(TM), DURECT’s post-surgical pain management investigational drug which is currently in Phase II clinical trials. Under the agreement, Hospira’s One 2 One(R) contract

CUPERTINO, Calif., Jan. 24 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that it has amended its development and commercialization agreement with Voyager Pharmaceutical Corporation governing Memryte(TM), an investigational drug under development for the treatment of Alzheimer’s disease based on DURECT’s proprietary DURIN(TM) Biodegradable Implant technology. Under the amendment, among other changes to the agreement,

CUPERTINO, Calif., Jan 03, 2007 /PRNewswire-FirstCall via COMTEX News Network/ — DURECT Corporation (Nasdaq: DRRX) today announced that we have started Phase II dosing in the U.S. under an FDA-accepted Investigational New Drug (IND) application for TRANSDUR(TM)-Bupivacaine (DUR-843), a transdermal pain patch for patients suffering from Post-Herpetic Neuralgia (post-shingles pain or PHN). DURECT’s Phase I

CUPERTINO, Calif., Dec. 18 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) today announced that Terrence F. Blaschke, M.D. has joined its Board of Directors. Dr. Blaschke has served on the faculty of Stanford University for over 30 years and is Professor of Medicine and Molecular Pharmacology (Active Emeritus) at the Stanford University School of Medicine. During

CUPERTINO, Calif., Dec. 11 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that it has successfully completed Phase I clinical trials with a new product, DUR-843, which is intended to treat a persistent pain condition. We believe that the persistent pain market remains underserved and that DUR-843 has the potential to provide several advantages over